106 related articles for article (PubMed ID: 26001120)
1. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer.
van der Sluis TC; van der Burg SH; Arens R; Melief CJ
Curr Opin Immunol; 2015 Aug; 35():9-14. PubMed ID: 26001120
[TBL] [Abstract][Full Text] [Related]
2. The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy.
Eiben GL; Velders MP; Kast WM
Adv Cancer Res; 2002; 86():113-48. PubMed ID: 12374277
[No Abstract] [Full Text] [Related]
3. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
5. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer.
Bellone S; Pecorelli S; Cannon MJ; Santin AD
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1473-86. PubMed ID: 17944571
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for gynaecological malignancies.
Coukos G; Conejo-Garcia JR; Roden RB; Wu TC
Expert Opin Biol Ther; 2005 Sep; 5(9):1193-210. PubMed ID: 16120050
[TBL] [Abstract][Full Text] [Related]
7. Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model.
Cerutti ML; Alonso LG; Tatti S; de Prat-Gay G
Int J Cancer; 2012 Apr; 130(8):1813-20. PubMed ID: 21780110
[TBL] [Abstract][Full Text] [Related]
8. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
9. Vaccine and antibody-directed T cell tumour immunotherapy.
Dermime S; Gilham DE; Shaw DM; Davidson EJ; Meziane el-K; Armstrong A; Hawkins RE; Stern PL
Biochim Biophys Acta; 2004 Jul; 1704(1):11-35. PubMed ID: 15238242
[TBL] [Abstract][Full Text] [Related]
10. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
11. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
12. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
13. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7.
Pilch H; Hoehn H; Schmidt M; Steiner E; Tanner B; Seufert R; Maeurer M
Zentralbl Gynakol; 2002; 124(8-9):406-12. PubMed ID: 12655469
[TBL] [Abstract][Full Text] [Related]
14. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
Mahdavi A; Monk BJ
Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
[TBL] [Abstract][Full Text] [Related]
15. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
[TBL] [Abstract][Full Text] [Related]
16. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.
Berraondo P; Nouzé C; Préville X; Ladant D; Leclerc C
Cancer Res; 2007 Sep; 67(18):8847-55. PubMed ID: 17875726
[TBL] [Abstract][Full Text] [Related]
17. [Papillomavirus infections and cervical tumorigenesis].
Kiyono T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):227-31. PubMed ID: 20235389
[No Abstract] [Full Text] [Related]
18. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.
Mansilla C; Berraondo P; Durantez M; Martínez M; Casares N; Arribillaga L; Rudilla F; Fioravanti J; Lozano T; Villanueva L; Sarobe P; Borrás F; Leclerc C; Prieto J; Lasarte JJ
Int J Cancer; 2012 Aug; 131(3):641-51. PubMed ID: 21898393
[TBL] [Abstract][Full Text] [Related]
19. [Biology of the papillomavirus infections: V. Vaccine developments].
Seilles E; Riethmuller D; Mougin C
Ann Biol Clin (Paris); 1999; 57(5):517-24. PubMed ID: 10518053
[TBL] [Abstract][Full Text] [Related]
20. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
